| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 220 | 2022 | 1577 | 8.780 |
Why?
|
| Prostate | 75 | 2022 | 437 | 3.980 |
Why?
|
| Prostatectomy | 99 | 2022 | 358 | 3.950 |
Why?
|
| Adenocarcinoma | 50 | 2022 | 1018 | 2.650 |
Why?
|
| Prostate-Specific Antigen | 54 | 2017 | 271 | 1.230 |
Why?
|
| Neoplasm Invasiveness | 41 | 2021 | 662 | 1.170 |
Why?
|
| Biomarkers, Tumor | 39 | 2017 | 1683 | 1.040 |
Why?
|
| Biopsy, Needle | 25 | 2021 | 234 | 0.990 |
Why?
|
| Neoplasm Recurrence, Local | 42 | 2017 | 1304 | 0.910 |
Why?
|
| Neoplasm Staging | 71 | 2017 | 1364 | 0.840 |
Why?
|
| Carcinoma, Ductal | 4 | 2020 | 9 | 0.840 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 11 | 2014 | 41 | 0.820 |
Why?
|
| Male | 259 | 2022 | 64952 | 0.800 |
Why?
|
| Seminal Vesicles | 17 | 2017 | 56 | 0.770 |
Why?
|
| Carcinoma, Transitional Cell | 14 | 2014 | 186 | 0.760 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2020 | 75 | 0.740 |
Why?
|
| Immunohistochemistry | 43 | 2013 | 1718 | 0.730 |
Why?
|
| Neoplasm Grading | 11 | 2022 | 302 | 0.720 |
Why?
|
| Urinary Bladder Neoplasms | 18 | 2014 | 541 | 0.710 |
Why?
|
| Pathology, Surgical | 7 | 2013 | 21 | 0.700 |
Why?
|
| Prognosis | 76 | 2021 | 5013 | 0.700 |
Why?
|
| Peripheral Nerves | 8 | 2021 | 88 | 0.670 |
Why?
|
| Terminology as Topic | 4 | 2025 | 232 | 0.670 |
Why?
|
| Aged | 137 | 2021 | 21456 | 0.640 |
Why?
|
| Humans | 293 | 2025 | 132081 | 0.640 |
Why?
|
| Middle Aged | 144 | 2021 | 28980 | 0.630 |
Why?
|
| Pathology, Clinical | 6 | 2020 | 24 | 0.620 |
Why?
|
| Prostatic Hyperplasia | 13 | 2005 | 122 | 0.580 |
Why?
|
| Epithelial Cells | 3 | 2016 | 903 | 0.560 |
Why?
|
| Carcinoma | 10 | 2020 | 300 | 0.550 |
Why?
|
| Cystectomy | 11 | 2014 | 165 | 0.550 |
Why?
|
| Apoptosis | 20 | 2014 | 1899 | 0.550 |
Why?
|
| Carcinoma in Situ | 6 | 2006 | 74 | 0.520 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2016 | 21 | 0.520 |
Why?
|
| Salmonella typhimurium | 1 | 2016 | 43 | 0.520 |
Why?
|
| Disease Progression | 46 | 2017 | 2232 | 0.510 |
Why?
|
| Specimen Handling | 9 | 2013 | 151 | 0.500 |
Why?
|
| Lymph Nodes | 11 | 2012 | 388 | 0.500 |
Why?
|
| Milk | 1 | 2016 | 108 | 0.490 |
Why?
|
| Endoribonucleases | 1 | 2016 | 85 | 0.490 |
Why?
|
| Polypropylenes | 1 | 2015 | 16 | 0.490 |
Why?
|
| Surgical Mesh | 2 | 2015 | 67 | 0.480 |
Why?
|
| Urinary Incontinence, Stress | 4 | 2014 | 34 | 0.470 |
Why?
|
| Neoplasm Metastasis | 16 | 2013 | 723 | 0.470 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2015 | 32 | 0.470 |
Why?
|
| Lymphatic Metastasis | 25 | 2012 | 443 | 0.460 |
Why?
|
| Genetic Therapy | 13 | 2011 | 720 | 0.460 |
Why?
|
| Macrophages | 5 | 2022 | 692 | 0.460 |
Why?
|
| Watchful Waiting | 4 | 2017 | 77 | 0.440 |
Why?
|
| Precancerous Conditions | 5 | 2014 | 278 | 0.430 |
Why?
|
| Urethra | 6 | 2014 | 89 | 0.430 |
Why?
|
| Sarcosine | 1 | 2013 | 8 | 0.410 |
Why?
|
| Predictive Value of Tests | 29 | 2020 | 2312 | 0.390 |
Why?
|
| Suburethral Slings | 2 | 2014 | 10 | 0.390 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 273 | 0.380 |
Why?
|
| Cadaver | 2 | 2010 | 119 | 0.340 |
Why?
|
| DNA, Neoplasm | 12 | 2005 | 295 | 0.340 |
Why?
|
| Adult | 85 | 2021 | 31558 | 0.320 |
Why?
|
| Lung Neoplasms | 8 | 2022 | 1541 | 0.320 |
Why?
|
| Multivariate Analysis | 22 | 2011 | 1440 | 0.310 |
Why?
|
| Urology | 5 | 2020 | 87 | 0.310 |
Why?
|
| Mammary Glands, Animal | 3 | 2016 | 451 | 0.300 |
Why?
|
| Inflammation | 1 | 2016 | 1522 | 0.300 |
Why?
|
| Follow-Up Studies | 32 | 2017 | 5407 | 0.300 |
Why?
|
| Thyroid Gland | 3 | 2005 | 104 | 0.300 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 7125 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2010 | 1285 | 0.290 |
Why?
|
| Prostatic Diseases | 2 | 1998 | 14 | 0.280 |
Why?
|
| Urogenital Neoplasms | 1 | 2008 | 14 | 0.280 |
Why?
|
| Caveolins | 6 | 2005 | 16 | 0.280 |
Why?
|
| Ganglia, Spinal | 5 | 2006 | 69 | 0.280 |
Why?
|
| Sensitivity and Specificity | 21 | 2021 | 2138 | 0.270 |
Why?
|
| DNA | 4 | 2010 | 1479 | 0.270 |
Why?
|
| Transforming Growth Factor beta | 9 | 2006 | 473 | 0.270 |
Why?
|
| Ethics, Medical | 1 | 2010 | 401 | 0.260 |
Why?
|
| Caveolin 1 | 9 | 2007 | 50 | 0.260 |
Why?
|
| Diagnosis, Differential | 15 | 2020 | 1966 | 0.260 |
Why?
|
| Thymidine Kinase | 9 | 2006 | 90 | 0.260 |
Why?
|
| Biopsy | 19 | 2020 | 1288 | 0.250 |
Why?
|
| Pleural Neoplasms | 2 | 2018 | 80 | 0.250 |
Why?
|
| Pelvis | 4 | 2021 | 73 | 0.250 |
Why?
|
| Mesothelioma | 2 | 2018 | 93 | 0.250 |
Why?
|
| Thyroid Diseases | 3 | 2005 | 29 | 0.250 |
Why?
|
| Parathyroid Diseases | 1 | 2005 | 2 | 0.250 |
Why?
|
| Frozen Sections | 1 | 2005 | 31 | 0.240 |
Why?
|
| Testicular Neoplasms | 4 | 2008 | 132 | 0.240 |
Why?
|
| Pathologists | 2 | 2023 | 30 | 0.240 |
Why?
|
| Parathyroid Glands | 1 | 2005 | 29 | 0.240 |
Why?
|
| Clitoris | 1 | 2025 | 4 | 0.240 |
Why?
|
| Pelvic Floor | 4 | 2021 | 39 | 0.230 |
Why?
|
| Cattle | 4 | 2016 | 569 | 0.230 |
Why?
|
| Thyroid Nodule | 2 | 2005 | 21 | 0.230 |
Why?
|
| Exocrine Glands | 1 | 2004 | 7 | 0.230 |
Why?
|
| Endocrine Glands | 1 | 2004 | 10 | 0.230 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 234 | 0.220 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 64 | 0.220 |
Why?
|
| Nuclear Proteins | 3 | 2010 | 1285 | 0.220 |
Why?
|
| Ploidies | 7 | 2004 | 38 | 0.220 |
Why?
|
| Reproducibility of Results | 15 | 2014 | 3015 | 0.210 |
Why?
|
| Ultrasonography | 19 | 2005 | 988 | 0.210 |
Why?
|
| Trans-Activators | 2 | 2008 | 712 | 0.210 |
Why?
|
| Disease-Free Survival | 16 | 2010 | 955 | 0.210 |
Why?
|
| Brachytherapy | 2 | 2003 | 95 | 0.210 |
Why?
|
| Retrospective Studies | 27 | 2021 | 17367 | 0.210 |
Why?
|
| Antigens, Neoplasm | 3 | 2018 | 403 | 0.210 |
Why?
|
| Signal Transduction | 5 | 2016 | 4718 | 0.210 |
Why?
|
| Cycloheximide | 1 | 2003 | 39 | 0.200 |
Why?
|
| Parotid Gland | 1 | 2002 | 21 | 0.200 |
Why?
|
| Salivary Glands, Minor | 1 | 2002 | 10 | 0.200 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2002 | 19 | 0.200 |
Why?
|
| Caseins | 1 | 2003 | 63 | 0.200 |
Why?
|
| Cell Cycle Proteins | 4 | 2010 | 685 | 0.200 |
Why?
|
| Prolactin | 1 | 2003 | 113 | 0.200 |
Why?
|
| NF-kappa B | 3 | 2008 | 454 | 0.190 |
Why?
|
| Milk Proteins | 1 | 2003 | 86 | 0.190 |
Why?
|
| Neoplasm Proteins | 6 | 2016 | 702 | 0.190 |
Why?
|
| Pathology | 3 | 2015 | 37 | 0.190 |
Why?
|
| Personnel Selection | 1 | 2023 | 69 | 0.190 |
Why?
|
| Preoperative Care | 6 | 2014 | 368 | 0.190 |
Why?
|
| Female | 48 | 2025 | 70699 | 0.190 |
Why?
|
| Multigene Family | 1 | 2002 | 305 | 0.180 |
Why?
|
| Base Sequence | 7 | 2004 | 2899 | 0.180 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2001 | 12 | 0.180 |
Why?
|
| Crystallization | 2 | 1998 | 89 | 0.180 |
Why?
|
| Inclusion Bodies | 2 | 1998 | 48 | 0.180 |
Why?
|
| Blotting, Western | 8 | 2010 | 1080 | 0.180 |
Why?
|
| Vulva | 1 | 2021 | 16 | 0.180 |
Why?
|
| Blotting, Northern | 5 | 2004 | 252 | 0.170 |
Why?
|
| Cytodiagnosis | 1 | 2021 | 21 | 0.170 |
Why?
|
| Transcription Factors | 5 | 2012 | 2491 | 0.170 |
Why?
|
| Kallikreins | 1 | 2000 | 30 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2018 | 2062 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2002 | 491 | 0.170 |
Why?
|
| Urinary Bladder | 6 | 2010 | 255 | 0.170 |
Why?
|
| Survival Analysis | 8 | 2017 | 1571 | 0.160 |
Why?
|
| Models, Biological | 5 | 2014 | 1445 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 4 | 2007 | 257 | 0.160 |
Why?
|
| Receptors, Transforming Growth Factor beta | 4 | 2004 | 106 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2016 | 1045 | 0.160 |
Why?
|
| Lymph Node Excision | 5 | 2005 | 173 | 0.160 |
Why?
|
| Adenoviridae | 9 | 2011 | 596 | 0.160 |
Why?
|
| Survival Rate | 10 | 2010 | 2192 | 0.160 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 3984 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 1 | 2021 | 157 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2009 | 502 | 0.160 |
Why?
|
| Cell Nucleus | 9 | 2011 | 592 | 0.160 |
Why?
|
| Neurites | 3 | 2006 | 45 | 0.160 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 1997 | 110 | 0.160 |
Why?
|
| Combined Modality Therapy | 12 | 2008 | 1294 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 122 | 0.160 |
Why?
|
| Receptors, Interleukin-6 | 4 | 2004 | 43 | 0.160 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 462 | 0.160 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 689 | 0.160 |
Why?
|
| Genitalia, Female | 1 | 2019 | 46 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 10 | 2009 | 605 | 0.150 |
Why?
|
| Vagina | 1 | 2021 | 205 | 0.150 |
Why?
|
| Urinary Tract | 1 | 2019 | 66 | 0.150 |
Why?
|
| DNA, Complementary | 4 | 2004 | 453 | 0.150 |
Why?
|
| Consensus | 5 | 2021 | 656 | 0.150 |
Why?
|
| Animals | 26 | 2016 | 34845 | 0.150 |
Why?
|
| Breast Neoplasms | 7 | 2007 | 2676 | 0.150 |
Why?
|
| Flutamide | 3 | 2004 | 27 | 0.150 |
Why?
|
| Cohort Studies | 14 | 2017 | 5169 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2007 | 449 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 2442 | 0.140 |
Why?
|
| Mice | 17 | 2016 | 18502 | 0.140 |
Why?
|
| Societies, Medical | 9 | 2021 | 778 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 569 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2005 | 613 | 0.140 |
Why?
|
| Androgen Antagonists | 3 | 2007 | 133 | 0.140 |
Why?
|
| Proportional Hazards Models | 13 | 2010 | 1460 | 0.140 |
Why?
|
| Cadherins | 4 | 2003 | 180 | 0.140 |
Why?
|
| Anticarcinogenic Agents | 3 | 2000 | 48 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1999 | 258 | 0.140 |
Why?
|
| Membrane Proteins | 7 | 2013 | 1597 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2018 | 36 | 0.140 |
Why?
|
| Ganciclovir | 8 | 2006 | 101 | 0.130 |
Why?
|
| RNA, Messenger | 8 | 2010 | 2680 | 0.130 |
Why?
|
| GPI-Linked Proteins | 1 | 2017 | 107 | 0.130 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2003 | 43 | 0.130 |
Why?
|
| RAW 264.7 Cells | 1 | 2016 | 46 | 0.130 |
Why?
|
| Salpingectomy | 1 | 2016 | 15 | 0.130 |
Why?
|
| Salmonella Infections | 1 | 2016 | 32 | 0.130 |
Why?
|
| Genes, erbB-1 | 1 | 2016 | 9 | 0.130 |
Why?
|
| Observer Variation | 5 | 2014 | 305 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2016 | 78 | 0.130 |
Why?
|
| Macrophages, Alveolar | 1 | 2016 | 47 | 0.130 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 3 | 2013 | 67 | 0.130 |
Why?
|
| Calcinosis | 1 | 1998 | 191 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 589 | 0.120 |
Why?
|
| Interleukin-6 | 3 | 2004 | 435 | 0.120 |
Why?
|
| DNA Primers | 5 | 2007 | 636 | 0.120 |
Why?
|
| Ovariectomy | 1 | 2016 | 170 | 0.120 |
Why?
|
| Cystadenoma, Papillary | 1 | 1995 | 4 | 0.120 |
Why?
|
| Pneumonectomy | 1 | 2017 | 148 | 0.120 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 1995 | 26 | 0.120 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 140 | 0.120 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1995 | 20 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2003 | 323 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 3 | 2007 | 63 | 0.120 |
Why?
|
| Isoenzymes | 4 | 2003 | 222 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2004 | 265 | 0.120 |
Why?
|
| Hip Prosthesis | 1 | 1995 | 10 | 0.120 |
Why?
|
| Histiocytosis | 1 | 1995 | 19 | 0.120 |
Why?
|
| Lymphatic Diseases | 1 | 1995 | 31 | 0.120 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2007 | 38 | 0.120 |
Why?
|
| Ki-67 Antigen | 7 | 2009 | 117 | 0.120 |
Why?
|
| Endarterectomy, Carotid | 1 | 2016 | 83 | 0.120 |
Why?
|
| Carcinoma, Papillary | 3 | 2001 | 93 | 0.120 |
Why?
|
| Epididymis | 1 | 1995 | 68 | 0.120 |
Why?
|
| Treatment Outcome | 20 | 2018 | 13015 | 0.110 |
Why?
|
| DNA Methylation | 3 | 2012 | 1122 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 2 | 2007 | 387 | 0.110 |
Why?
|
| Vascular Calcification | 1 | 2016 | 71 | 0.110 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 494 | 0.110 |
Why?
|
| Tissue Kallikreins | 3 | 2003 | 7 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 1307 | 0.110 |
Why?
|
| RNA, Neoplasm | 3 | 2006 | 136 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 137 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2016 | 200 | 0.110 |
Why?
|
| Mucoproteins | 1 | 1994 | 12 | 0.110 |
Why?
|
| Tissue Array Analysis | 6 | 2010 | 139 | 0.110 |
Why?
|
| Simplexvirus | 7 | 2006 | 100 | 0.110 |
Why?
|
| Paraganglia, Chromaffin | 1 | 1994 | 1 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 1997 | 0.110 |
Why?
|
| Acyclovir | 2 | 2004 | 47 | 0.110 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 153 | 0.110 |
Why?
|
| Medical Records | 2 | 2013 | 189 | 0.110 |
Why?
|
| Pain Measurement | 1 | 2015 | 351 | 0.110 |
Why?
|
| Logistic Models | 9 | 2007 | 1836 | 0.110 |
Why?
|
| Cytoplasm | 3 | 2010 | 269 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 109 | 0.110 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 3689 | 0.110 |
Why?
|
| Professional Role | 1 | 2014 | 73 | 0.100 |
Why?
|
| Valine | 2 | 2004 | 111 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2003 | 770 | 0.100 |
Why?
|
| Stromal Cells | 6 | 2007 | 304 | 0.100 |
Why?
|
| Peptides | 2 | 2017 | 844 | 0.100 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2013 | 6 | 0.100 |
Why?
|
| Time Factors | 9 | 2007 | 6443 | 0.100 |
Why?
|
| Nomograms | 2 | 2010 | 38 | 0.100 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cell Communication | 3 | 2003 | 186 | 0.100 |
Why?
|
| Molecular Sequence Data | 4 | 2009 | 3770 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 451 | 0.100 |
Why?
|
| Erectile Dysfunction | 3 | 2017 | 211 | 0.100 |
Why?
|
| Databases as Topic | 1 | 2013 | 76 | 0.100 |
Why?
|
| Coculture Techniques | 4 | 2006 | 238 | 0.100 |
Why?
|
| Quality of Life | 4 | 2013 | 2159 | 0.100 |
Why?
|
| Histocytological Preparation Techniques | 2 | 2010 | 5 | 0.090 |
Why?
|
| Antiviral Agents | 8 | 2006 | 823 | 0.090 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 66 | 0.090 |
Why?
|
| Microscopy, Electron | 3 | 1998 | 341 | 0.090 |
Why?
|
| Risk Assessment | 9 | 2017 | 3727 | 0.090 |
Why?
|
| Menorrhagia | 1 | 2013 | 82 | 0.090 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2013 | 94 | 0.090 |
Why?
|
| Palpation | 7 | 2003 | 18 | 0.090 |
Why?
|
| Patient Selection | 5 | 2016 | 730 | 0.090 |
Why?
|
| Genes, Suppressor | 1 | 2011 | 12 | 0.090 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2002 | 261 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2004 | 633 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 188 | 0.090 |
Why?
|
| Postoperative Period | 3 | 2007 | 334 | 0.090 |
Why?
|
| Transcriptome | 1 | 2018 | 1125 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2016 | 295 | 0.090 |
Why?
|
| Salvage Therapy | 4 | 2003 | 200 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 413 | 0.080 |
Why?
|
| Genetic Vectors | 7 | 2011 | 926 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 1126 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2004 | 686 | 0.080 |
Why?
|
| Tumor Burden | 4 | 2014 | 248 | 0.080 |
Why?
|
| United States | 9 | 2023 | 11652 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2003 | 92 | 0.080 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 3 | 2005 | 38 | 0.080 |
Why?
|
| Thyroid Neoplasms | 3 | 1995 | 250 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 663 | 0.080 |
Why?
|
| Regression Analysis | 5 | 2007 | 796 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 1997 | 1037 | 0.080 |
Why?
|
| Risk Factors | 6 | 2015 | 10936 | 0.080 |
Why?
|
| Sural Nerve | 2 | 2001 | 46 | 0.080 |
Why?
|
| Genes, erbB-2 | 2 | 2007 | 38 | 0.080 |
Why?
|
| Adenoma | 3 | 2004 | 145 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 1990 | 42 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2014 | 862 | 0.080 |
Why?
|
| Oncogenes | 1 | 2010 | 175 | 0.080 |
Why?
|
| Visceral Prolapse | 1 | 2009 | 2 | 0.080 |
Why?
|
| Uterine Prolapse | 1 | 2009 | 21 | 0.080 |
Why?
|
| Thymus Neoplasms | 1 | 1990 | 39 | 0.080 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 2669 | 0.080 |
Why?
|
| Metabolomics | 1 | 2013 | 479 | 0.080 |
Why?
|
| Quantum Dots | 1 | 2009 | 15 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 6 | 2010 | 249 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 62 | 0.080 |
Why?
|
| Loperamide | 1 | 2008 | 8 | 0.080 |
Why?
|
| Asbestosis | 1 | 1988 | 2 | 0.070 |
Why?
|
| Asbestos | 1 | 1988 | 11 | 0.070 |
Why?
|
| Affective Symptoms | 1 | 2009 | 63 | 0.070 |
Why?
|
| Laboratories, Hospital | 1 | 2008 | 24 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 6 | 2006 | 133 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2008 | 47 | 0.070 |
Why?
|
| Pyrazines | 1 | 2008 | 72 | 0.070 |
Why?
|
| Fecal Incontinence | 1 | 2008 | 78 | 0.070 |
Why?
|
| ROC Curve | 5 | 2017 | 600 | 0.070 |
Why?
|
| Mucous Membrane | 2 | 2001 | 90 | 0.070 |
Why?
|
| Receptors, Androgen | 3 | 2007 | 410 | 0.070 |
Why?
|
| Urinary Incontinence, Urge | 1 | 2007 | 5 | 0.070 |
Why?
|
| Bronchi | 1 | 1988 | 103 | 0.070 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 227 | 0.070 |
Why?
|
| Granulosa Cell Tumor | 1 | 2008 | 39 | 0.070 |
Why?
|
| Sputum | 1 | 1988 | 116 | 0.070 |
Why?
|
| Urodynamics | 1 | 2007 | 40 | 0.070 |
Why?
|
| Biological Evolution | 1 | 2009 | 243 | 0.070 |
Why?
|
| Cell Division | 4 | 2004 | 744 | 0.070 |
Why?
|
| Probability | 6 | 2008 | 322 | 0.070 |
Why?
|
| Renal Artery | 1 | 1988 | 69 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2013 | 749 | 0.070 |
Why?
|
| Histocytochemistry | 2 | 1998 | 92 | 0.070 |
Why?
|
| Recovery of Function | 2 | 2007 | 462 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 3 | 2007 | 549 | 0.070 |
Why?
|
| Aneurysm | 1 | 1988 | 82 | 0.070 |
Why?
|
| Analysis of Variance | 6 | 2001 | 1007 | 0.070 |
Why?
|
| Informed Consent | 1 | 2010 | 346 | 0.070 |
Why?
|
| In Situ Hybridization | 6 | 2007 | 469 | 0.070 |
Why?
|
| Systems Biology | 1 | 2007 | 62 | 0.070 |
Why?
|
| Hyperplasia | 2 | 1999 | 196 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2003 | 826 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2007 | 142 | 0.060 |
Why?
|
| Neurogenesis | 1 | 2008 | 222 | 0.060 |
Why?
|
| Case-Control Studies | 5 | 2011 | 3414 | 0.060 |
Why?
|
| Phenotype | 3 | 2012 | 4539 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2004 | 764 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 2008 | 269 | 0.060 |
Why?
|
| Genome | 1 | 2009 | 504 | 0.060 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2003 | 36 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2010 | 2510 | 0.060 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 39 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2005 | 207 | 0.060 |
Why?
|
| Genes, p53 | 2 | 1997 | 221 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 127 | 0.060 |
Why?
|
| Genital Neoplasms, Male | 2 | 2003 | 12 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2007 | 234 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 1134 | 0.060 |
Why?
|
| Evolution, Molecular | 2 | 2009 | 699 | 0.060 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2005 | 56 | 0.060 |
Why?
|
| Psychometrics | 1 | 2009 | 693 | 0.060 |
Why?
|
| False Negative Reactions | 2 | 2004 | 89 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2007 | 211 | 0.060 |
Why?
|
| Neoplasms | 2 | 2014 | 2953 | 0.060 |
Why?
|
| Pericardium | 1 | 2005 | 91 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 6 | 2003 | 1045 | 0.060 |
Why?
|
| Organ Size | 2 | 2008 | 447 | 0.060 |
Why?
|
| Risk | 3 | 2014 | 761 | 0.060 |
Why?
|
| Adenomatoid Tumor | 1 | 2004 | 1 | 0.060 |
Why?
|
| Endonucleases | 1 | 2004 | 50 | 0.060 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 2001 | 4 | 0.060 |
Why?
|
| Integrin beta1 | 1 | 2004 | 56 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2006 | 243 | 0.050 |
Why?
|
| Heart Neoplasms | 1 | 2005 | 105 | 0.050 |
Why?
|
| Hemangioma | 1 | 2005 | 97 | 0.050 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 2004 | 5 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2004 | 7 | 0.050 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2004 | 10 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2004 | 66 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 743 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2004 | 99 | 0.050 |
Why?
|
| Hypercalcemia | 1 | 2004 | 42 | 0.050 |
Why?
|
| CD36 Antigens | 1 | 2004 | 42 | 0.050 |
Why?
|
| Mutation | 2 | 2010 | 6250 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2004 | 83 | 0.050 |
Why?
|
| Amino Acid Transport System ASC | 1 | 2003 | 6 | 0.050 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2003 | 36 | 0.050 |
Why?
|
| Alternative Splicing | 2 | 2009 | 364 | 0.050 |
Why?
|
| Forecasting | 5 | 2005 | 372 | 0.050 |
Why?
|
| Recurrence | 4 | 2012 | 1452 | 0.050 |
Why?
|
| Treatment Failure | 4 | 1999 | 363 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2004 | 133 | 0.050 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2003 | 17 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 3 | 2009 | 1802 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2019 | 1230 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2003 | 1670 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 165 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2002 | 60 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 231 | 0.050 |
Why?
|
| Proteins | 2 | 2009 | 1038 | 0.050 |
Why?
|
| Lipocalin 1 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 26 | 0.050 |
Why?
|
| Immunoassay | 1 | 2003 | 135 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 343 | 0.050 |
Why?
|
| Aging | 2 | 2007 | 1254 | 0.050 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 478 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 2001 | 142 | 0.050 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2002 | 11 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2003 | 99 | 0.050 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2002 | 30 | 0.050 |
Why?
|
| Exercise | 1 | 2008 | 860 | 0.050 |
Why?
|
| Prospective Studies | 7 | 2018 | 6557 | 0.050 |
Why?
|
| STAT5 Transcription Factor | 1 | 2003 | 89 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2008 | 802 | 0.050 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1982 | 16 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2010 | 1829 | 0.050 |
Why?
|
| Mammography | 1 | 2003 | 133 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2002 | 10 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 149 | 0.050 |
Why?
|
| Up-Regulation | 4 | 2006 | 881 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2002 | 100 | 0.050 |
Why?
|
| Phylogeny | 1 | 2004 | 763 | 0.050 |
Why?
|
| Penile Erection | 2 | 2000 | 86 | 0.050 |
Why?
|
| Endometriosis | 1 | 2004 | 175 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 816 | 0.050 |
Why?
|
| Antigens, CD | 3 | 2004 | 436 | 0.050 |
Why?
|
| Age Factors | 4 | 2016 | 2921 | 0.050 |
Why?
|
| Granuloma | 1 | 1982 | 66 | 0.050 |
Why?
|
| Lipoxygenase | 1 | 2001 | 3 | 0.050 |
Why?
|
| Hydroxyl Radical | 1 | 2001 | 13 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 584 | 0.050 |
Why?
|
| Keratins | 3 | 2003 | 52 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 348 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 811 | 0.040 |
Why?
|
| Clinical Trials as Topic | 4 | 2007 | 1161 | 0.040 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2001 | 2 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 444 | 0.040 |
Why?
|
| Guanine | 1 | 2001 | 61 | 0.040 |
Why?
|
| Photomicrography | 1 | 2021 | 11 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2002 | 615 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2004 | 439 | 0.040 |
Why?
|
| Urologists | 1 | 2021 | 12 | 0.040 |
Why?
|
| Models, Statistical | 3 | 2014 | 494 | 0.040 |
Why?
|
| Fascia | 1 | 2021 | 16 | 0.040 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2021 | 23 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2004 | 682 | 0.040 |
Why?
|
| Sacrococcygeal Region | 1 | 2021 | 36 | 0.040 |
Why?
|
| Mucins | 1 | 2021 | 72 | 0.040 |
Why?
|
| Oligospermia | 2 | 1997 | 62 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2021 | 105 | 0.040 |
Why?
|
| Epithelium | 4 | 2004 | 354 | 0.040 |
Why?
|
| Adenine | 1 | 2001 | 119 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2002 | 443 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2006 | 89 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2001 | 81 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2002 | 377 | 0.040 |
Why?
|
| Algorithms | 5 | 2008 | 1725 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 462 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 243 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 240 | 0.040 |
Why?
|
| Ligaments | 1 | 2019 | 21 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2000 | 77 | 0.040 |
Why?
|
| Spermatogenesis | 2 | 1997 | 176 | 0.040 |
Why?
|
| Introns | 1 | 2000 | 305 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2010 | 1612 | 0.040 |
Why?
|
| Internationality | 2 | 2010 | 132 | 0.040 |
Why?
|
| Activin Receptors, Type I | 1 | 1999 | 35 | 0.040 |
Why?
|
| Leptin | 1 | 2001 | 219 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 101 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 1255 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2000 | 173 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 86 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2000 | 156 | 0.040 |
Why?
|
| RNA | 1 | 2002 | 552 | 0.040 |
Why?
|
| Actuarial Analysis | 4 | 1997 | 30 | 0.040 |
Why?
|
| Staining and Labeling | 3 | 2004 | 181 | 0.040 |
Why?
|
| Prostatitis | 1 | 1998 | 16 | 0.040 |
Why?
|
| Atrophy | 1 | 1999 | 251 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 1982 | 740 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 221 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 325 | 0.040 |
Why?
|
| S100 Proteins | 3 | 2005 | 47 | 0.040 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 6 | 0.040 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 1998 | 7 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 1249 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2009 | 3086 | 0.040 |
Why?
|
| Penis | 1 | 1999 | 101 | 0.040 |
Why?
|
| DNA Damage | 1 | 2001 | 511 | 0.040 |
Why?
|
| Gene Expression | 1 | 2002 | 1563 | 0.040 |
Why?
|
| Pleura | 1 | 2018 | 28 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 4 | 2010 | 1555 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 451 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2011 | 400 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2016 | 761 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 125 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2007 | 503 | 0.030 |
Why?
|
| Observation | 1 | 2017 | 43 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2002 | 1050 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3852 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2003 | 3045 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2009 | 239 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2009 | 424 | 0.030 |
Why?
|
| Clodronic Acid | 1 | 2016 | 4 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 79 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cetuximab | 1 | 2016 | 13 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 15 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 356 | 0.030 |
Why?
|
| Review Literature as Topic | 2 | 2007 | 49 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 356 | 0.030 |
Why?
|
| Proteogenomics | 1 | 2018 | 110 | 0.030 |
Why?
|
| Uteroglobin | 1 | 2016 | 41 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2016 | 65 | 0.030 |
Why?
|
| Incidence | 3 | 2000 | 3370 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 43 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2006 | 124 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 689 | 0.030 |
Why?
|
| Point Mutation | 1 | 1997 | 349 | 0.030 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2017 | 107 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 1997 | 228 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1996 | 77 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1995 | 38 | 0.030 |
Why?
|
| Testis | 1 | 1997 | 423 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1995 | 15 | 0.030 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2007 | 25 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 377 | 0.030 |
Why?
|
| Histological Techniques | 1 | 1994 | 21 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 507 | 0.030 |
Why?
|
| Caspases | 2 | 2006 | 166 | 0.030 |
Why?
|
| Voluntary Health Agencies | 1 | 2014 | 5 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 2451 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2014 | 25 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 347 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 30 | 0.030 |
Why?
|
| New Zealand | 1 | 2014 | 60 | 0.030 |
Why?
|
| Uromodulin | 1 | 1994 | 11 | 0.030 |
Why?
|
| Infertility, Male | 1 | 1997 | 296 | 0.030 |
Why?
|
| Synaptophysin | 1 | 1994 | 20 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 770 | 0.030 |
Why?
|
| Chromogranins | 1 | 1994 | 28 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1994 | 31 | 0.030 |
Why?
|
| Prodrugs | 2 | 2004 | 63 | 0.030 |
Why?
|
| Individuality | 1 | 1994 | 37 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2004 | 237 | 0.030 |
Why?
|
| Antibodies | 2 | 2006 | 366 | 0.030 |
Why?
|
| Health Surveys | 1 | 2014 | 259 | 0.030 |
Why?
|
| Dysmenorrhea | 1 | 2013 | 15 | 0.030 |
Why?
|
| Australasia | 1 | 2013 | 6 | 0.030 |
Why?
|
| Cell Survival | 2 | 2006 | 868 | 0.030 |
Why?
|
| Leuprolide | 2 | 2004 | 23 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 84 | 0.020 |
Why?
|
| Tranexamic Acid | 1 | 2013 | 33 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 105 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2004 | 37 | 0.020 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 49 | 0.020 |
Why?
|
| Reproductive Health | 1 | 2013 | 49 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2014 | 754 | 0.020 |
Why?
|
| United Kingdom | 1 | 2013 | 234 | 0.020 |
Why?
|
| Rectum | 4 | 1994 | 114 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 165 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2013 | 219 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 2 | 2003 | 127 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 608 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 246 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 940 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1994 | 503 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 305 | 0.020 |
Why?
|
| Adolescent | 5 | 2008 | 20530 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2001 | 327 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 541 | 0.020 |
Why?
|
| Boston | 1 | 2010 | 122 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 99 | 0.020 |
Why?
|
| Cytokines | 1 | 2016 | 1365 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 1556 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1990 | 23 | 0.020 |
Why?
|
| Mucin-1 | 1 | 1990 | 38 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1990 | 97 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 348 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 93 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2009 | 33 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 61 | 0.020 |
Why?
|
| Synteny | 1 | 2009 | 77 | 0.020 |
Why?
|
| Cisplatin | 1 | 2010 | 282 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 2008 | 25 | 0.020 |
Why?
|
| Mice, Inbred C3H | 2 | 2000 | 118 | 0.020 |
Why?
|
| Semaphorins | 1 | 2008 | 33 | 0.020 |
Why?
|
| Bortezomib | 1 | 2008 | 70 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 1350 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2007 | 1700 | 0.020 |
Why?
|
| Species Specificity | 1 | 2009 | 542 | 0.020 |
Why?
|
| Accreditation | 1 | 2008 | 93 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 2004 | 445 | 0.020 |
Why?
|
| Patient Care Management | 1 | 2008 | 66 | 0.020 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 144 | 0.020 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 1988 | 22 | 0.020 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2007 | 2 | 0.020 |
Why?
|
| North America | 1 | 2008 | 265 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 297 | 0.020 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1988 | 41 | 0.020 |
Why?
|
| Physicians | 1 | 2014 | 637 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1990 | 421 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 56 | 0.020 |
Why?
|
| Europe | 1 | 2008 | 373 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2003 | 2163 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 62 | 0.020 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2007 | 18 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 618 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2007 | 41 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 588 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2007 | 49 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2008 | 259 | 0.020 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2007 | 97 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 4 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 35 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2017 | 3129 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 515 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 711 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 767 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1284 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2006 | 29 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 1988 | 234 | 0.020 |
Why?
|
| CpG Islands | 1 | 2007 | 342 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2005 | 56 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 69 | 0.020 |
Why?
|
| Cholinesterases | 1 | 2005 | 10 | 0.020 |
Why?
|
| Neuroanatomy | 1 | 2005 | 13 | 0.020 |
Why?
|
| Histoplasmosis | 1 | 1986 | 55 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1988 | 263 | 0.010 |
Why?
|
| Carcinogens | 1 | 2005 | 128 | 0.010 |
Why?
|
| Gold Radioisotopes | 1 | 1985 | 2 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1985 | 5 | 0.010 |
Why?
|
| Follicular Phase | 1 | 2004 | 15 | 0.010 |
Why?
|
| Luteal Phase | 1 | 2004 | 9 | 0.010 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 68 | 0.010 |
Why?
|
| World Health Organization | 1 | 2005 | 114 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2005 | 239 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2010 | 843 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2004 | 24 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2004 | 26 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 53 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2006 | 4758 | 0.010 |
Why?
|
| Genistein | 1 | 2004 | 39 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 277 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 119 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 2004 | 31 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2005 | 254 | 0.010 |
Why?
|
| Sulfones | 1 | 2004 | 73 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 88 | 0.010 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2004 | 9 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2004 | 141 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1757 | 0.010 |
Why?
|
| Kidney | 2 | 1988 | 1338 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2008 | 574 | 0.010 |
Why?
|
| Parathyroid Neoplasms | 1 | 2004 | 24 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 433 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 105 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 526 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 20 | 0.010 |
Why?
|
| Nitriles | 1 | 2004 | 155 | 0.010 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2003 | 30 | 0.010 |
Why?
|
| Physical Examination | 2 | 1994 | 165 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 169 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2003 | 39 | 0.010 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 35 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 99 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 131 | 0.010 |
Why?
|
| Rare Diseases | 1 | 2005 | 208 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2006 | 1963 | 0.010 |
Why?
|
| Pressure | 1 | 2003 | 131 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 1986 | 237 | 0.010 |
Why?
|
| Lactation | 1 | 2004 | 198 | 0.010 |
Why?
|
| Cyclin A | 1 | 2002 | 17 | 0.010 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2002 | 20 | 0.010 |
Why?
|
| Keratin-20 | 1 | 2002 | 12 | 0.010 |
Why?
|
| Keratin-7 | 1 | 2002 | 8 | 0.010 |
Why?
|
| Intermediate Filament Proteins | 1 | 2002 | 26 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 803 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 673 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1982 | 57 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1982 | 13 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1580 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2009 | 916 | 0.010 |
Why?
|
| Lymphatic Irradiation | 1 | 2001 | 4 | 0.010 |
Why?
|
| Leukopenia | 1 | 1982 | 47 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 818 | 0.010 |
Why?
|
| Endometrium | 1 | 2004 | 277 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 174 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 270 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1982 | 249 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2003 | 396 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2001 | 92 | 0.010 |
Why?
|
| Laminin | 1 | 2001 | 72 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 334 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2001 | 41 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 1224 | 0.010 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2001 | 4 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2001 | 70 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1348 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 2001 | 67 | 0.010 |
Why?
|
| Agar | 1 | 2001 | 18 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 99 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 1685 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2004 | 448 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 801 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2002 | 256 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2001 | 125 | 0.010 |
Why?
|
| Luciferases | 1 | 2001 | 129 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 343 | 0.010 |
Why?
|
| Catalysis | 1 | 2001 | 139 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 280 | 0.010 |
Why?
|
| Chaperonins | 1 | 2000 | 15 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2000 | 40 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 728 | 0.010 |
Why?
|
| Thiazoles | 1 | 2001 | 99 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 92 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1982 | 327 | 0.010 |
Why?
|
| Culture Media | 1 | 2001 | 182 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2001 | 351 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 364 | 0.010 |
Why?
|
| Collagen | 1 | 2001 | 303 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 173 | 0.010 |
Why?
|
| Fenretinide | 1 | 2000 | 9 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2003 | 698 | 0.010 |
Why?
|
| Herpesviridae | 1 | 2000 | 34 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 179 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 210 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 437 | 0.010 |
Why?
|
| Body Height | 1 | 2001 | 204 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 383 | 0.010 |
Why?
|
| Defective Viruses | 1 | 1999 | 17 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1883 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2001 | 208 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 134 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 751 | 0.010 |
Why?
|
| Elasticity | 1 | 1998 | 78 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2724 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2001 | 418 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 3868 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 3604 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 666 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1998 | 76 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1996 | 8 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1996 | 23 | 0.010 |
Why?
|
| Biotin | 1 | 1996 | 44 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2003 | 1072 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1996 | 49 | 0.010 |
Why?
|
| Capillaries | 1 | 1996 | 71 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1998 | 388 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 9938 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1997 | 409 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 1423 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 70 | 0.010 |
Why?
|
| Virus Replication | 1 | 1999 | 636 | 0.010 |
Why?
|
| CD57 Antigens | 1 | 1995 | 5 | 0.010 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1995 | 10 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1995 | 17 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 1204 | 0.010 |
Why?
|
| Testosterone | 1 | 2001 | 611 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1997 | 821 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1995 | 618 | 0.010 |
Why?
|
| Mitosis | 1 | 1994 | 199 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1995 | 826 | 0.010 |
Why?
|
| Exons | 1 | 1995 | 806 | 0.010 |
Why?
|
| Remission Induction | 1 | 1992 | 306 | 0.010 |
Why?
|
| Cerebellar Neoplasms | 1 | 1995 | 461 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2000 | 4687 | 0.000 |
Why?
|
| Mass Screening | 1 | 1994 | 830 | 0.000 |
Why?
|
| Texas | 1 | 1996 | 3632 | 0.000 |
Why?
|
| Aorta, Abdominal | 1 | 1986 | 118 | 0.000 |
Why?
|
| Child | 1 | 2005 | 25758 | 0.000 |
Why?
|
| Kidney Failure, Chronic | 1 | 1988 | 952 | 0.000 |
Why?
|